Comparative Efficacy And Safety Of Gemtuzumab Ozogamicin (Go) Plus Daunorubicin-Cytarabine Combination And Comparators As Induction Therapy For Newly Diagnosed Acute Myeloid Leukemia

INTRODUCTION: Acute myeloid leukemia (AML) is the most common form of acute leukemia. Induction therapy usually consists of a cytarabine-anthracycline combination, such as daunorubicin and cytarabine (DA), a regimen which has been in use for over 30 years. There have been few advances in treatment and thus there are few options for induction therapies that prolong remission. Gemtuzumab ozogamicin (GO) was approved in the United States in 2000 as a treatment for relapsed AML. Although withdrawn in 2010, data from recent randomized controlled trials (RCTs) showed a lower dose of GO (3 mg/m2) in combination with DA led to improved event-free survival (EFS), relapse-free survival (RFS), and overall survival (OS) in the newly-diagnosed setting.